EDSA Edesa Biotech, Inc. stock chart & analysis
Conviction 40HealthcareScan · Fri, Nov 6, 2026Edesa Biotech, Inc. (EDSA) closed at $2.14 (+0.47%) on Nov 6, 2026. Price is below its 50-day and below its 200-day moving average. RSI(14) 28, RS Rating 99, -89.2% from its 52-week high, +54.2% year to date. Sector: Healthcare · Pharmaceutical Preparations.
Why EDSA moved
From the StockSetups movers recaps that covered EDSA, newest first. A recap states what was known that day.
- Premarket+36.1%
Edesa Biotech is up 36.1% premarket, at $2.98, on 20,864,289 shares versus a 20-day average of 46,001. Market cap is only $21.1M.
Premarket Movers Nov 9, 2026: Why CKX, GFR, EDSA Are Up →
Financials as of Tue, Jun 30, 2026 · quarterly.
EDSA technical analysis
Trend
EDSA is in a downtrend: price is below the 50-day, which is below the 200-day moving average. It closed 38.2% below the 50-day ($3.54) and 61.4% below the 200-day ($5.68). ADX(14) at 32 points to a strong, established trend. It meets 3 of 8 trend-template criteria.
Momentum
RSI(14) is 28, in oversold territory. MACD crossed below its signal line one session ago. Its RS Rating of 99 puts its weighted 12-month performance ahead of about 99% of the US market.
Volume and volatility
Volume on the latest session ran 0.3× its 20-day average. It trades about $120,383 a day on average. ATR(14) is $0.2498, 11.4% of price — its typical daily range. On-balance volume is trending down. Chaikin Money Flow (-0.43) shows distribution.
Key levels
The chart pattern's support is $2.49 and its resistance $4.24. The 52-week range is $0.7200 to $20.32; price is 89.2% below the high and 204.2% above the low. The VWAP anchored at the 52-week high is $8.89, above price.
Performance
EDSA returned -14.8% (1 week), -40.2% (1 month), -58.2% (3 months), -86.6% (6 months), +29.6% (1 year), +54.2% (year to date).
About Edesa Biotech, Inc.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.
Pharmaceutical Preparations · Listed 2010 · 17 employees
Recent news
- Edesa Biotech Grants Kyorin Japanese Rights to ParidiprubartTipRanks · Mon, Nov 9, 2026
- Edesa Biotech Signs Japan Licensing Agreement With Kyorin for Paridiprubart Worth Up to $146 MillionAdvfn · Mon, Nov 9, 2026
- Edesa Biotech (EDSA) Partners with KYORIN Pharmaceutical for ParGuruFocus · Mon, Nov 9, 2026
- Form 8K EDESA BIOTECH For: 9 November By Investing.comInvesting.com Canada · Mon, Nov 9, 2026
- Edesa Biotech licenses ARDS drug to Kyorin for Japan market By Investing.comInvesting.com India · Mon, Nov 9, 2026
- Edesa Biotech Announces Agreement with KYORIN Pharmaceutical to Develop and Commercialize Paridiprubart in JapanYahoo Finance · Mon, Nov 9, 2026
- Edesa Biotech Stock Price Forecast. Should You Buy EDSA?StockInvest.us · Fri, Nov 6, 2026
- An 18,677-unit CEO stock grant vested in full upon grant at Edesa Biotech (EDSA).Stock Titan · Thu, Nov 5, 2026
- Edesa Biotech to Present at Guggenheim Healthcare Innovation ConferenceYahoo Finance · Wed, Nov 4, 2026
- EDSA: Edesa Biotech Inc Latest Stock Price, Analysis, News and Trading IdeasStocktwits · Tue, Jun 11, 2019
Insider activity
SEC Form 4 transactions in EDSA
| Insider | Side | Shares | Value | Traded | Filed |
|---|---|---|---|---|---|
Nijhawan Pardeep Chief Executive Officer · Common Shares · 2026-11-04 | Grant | 18.68K | — | 2026-11-04 | 2026-11-05 |
Nijhawan Pardeep Chief Executive Officer · Common Shares · 2026-10-28 | Grant | 27.6K | — | 2026-10-28 | 2026-10-29 |
Nijhawan Pardeep Chief Executive Officer · Common Shares · 2026-06-01 | Other | — | — | 2026-06-01 | 2026-06-01 |
Nijhawan Pardeep Chief Executive Officer · Common Shares · 2026-06-01 | Grant | 1.67K | $0 | 2026-06-01 | 2026-06-01 |
Marshall Patrick Director · Common Shares · 2026-05-27 | Other | — | — | 2026-05-27 | 2026-05-29 |
Sistilli Carlo Director · Common Shares · 2026-05-27 | Other | — | — | 2026-05-27 | 2026-05-29 |
Sistilli Carlo Director · Common Shares · 2026-05-27 | Grant | 19K | $0 | 2026-05-27 | 2026-05-29 |
Marshall Patrick Director · Common Shares · 2026-05-27 | Grant | 19K | $0 | 2026-05-27 | 2026-05-29 |
Brooks Michael J President · Common Shares · 2026-05-27 | Grant | 64.61K | $0 | 2026-05-27 | 2026-05-29 |
Nijhawan Pardeep Chief Executive Officer · Common Shares · 2026-05-27 | Grant | 96.91K | $0 | 2026-05-27 | 2026-05-29 |
SEC filings
EDGAR filings in EDSA · 10 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, no credit card.
Start free — 7-day trial, no card →Free daily signals by email. Top 3 setups per lane after every close. No account needed.
Unsubscribe anytime · Privacy
Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.